News

Specifically, the nitric oxide-releasing technology was found to be effective against Acinetobacter baumannii, a gram-negative bacterium resistant to nearly all antibiotics, which causes pneumonia, urinary tract infection, and

The aproval follows two clinical trials that evaluated the safety and effectiveness of Cerdelga in 199 participants with the disease that is estimated to affect nearly 6,000 people

The agreement also includes an option for Novartis to acquire the rest of the company for a cash payment of approximately $165m. In addition, Gamida Cell will be

Earlier this month, Sandoz launched Vitaros in Sweden. Richard Pascoe, Chief Executive Officer of Apricus, commented, "We are pleased to announce the launch of Vitaros in Germany, one

The key component of the MOU provides that "Sinopharm-CSIPI and Sinopharm A-THINK desire to obtain an exclusive license to commercialize PV-10 within [the People’s Republic of] China territory,

"Hearing loss is the third most common physical ailment behind arthritis and heart disease," noted Audra McRae, PharPoint’s Chief Operating Officer. "Using our team’s experience we are excited

So far, Acetylcysteine Solution, USP vial for inhalation (mucolytic agent) or oral administration has been on the drug-shortage lists maintained by both the US Food and Drug Administration

The trial is being carried out at Columbia University and the New York State Psychiatric Institute, and led by Dr. Sandra Comer, Professor of Neurobiology and principal investigator.

These technologies are applicable to EastGate’s existing pharmaceutical products in development and can also be employed as effective platforms for delivery of other biologically active compounds. The company